Mensia Technologies

Based in Rennes, Paris and Boston, Mensia Technologies is a revenue-generating medical device company developing ground-breaking, home-care medical solutions for the care of the Central Nervous System (CNS).

Our first product is a fully automated personalized neurofeedback training (NFT) system for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). We are currently testing it in the largest randomized clinical trial of its kind in 5 European countries. This medical device, Mensia Koala, once clinically validated, will provide an alternative to symptomatic psychoactive medication like methylphenidate (MPH) and will be made available to patients through prescription.

On a 5-year horizon, and beyond ADHD, we intend to leverage our proprietary, real-time brain signal processing, and know-how in neurosciences to develop or co-develop additional game-changing medical devices in pathologies such as chronic pain, the cognitive impairment of seniors or motor function rehabilitation.